



Patent Department - RY 60-30  
Merck & Co., Inc.  
P.O. Box 2000  
Rahway, NJ 07065

RECEIVED  
CENTRAL FAX CENTER

JUL 22 2008

**FACSIMILE COVER SHEET**

Date: July 22, 2008

Please deliver the following message to:

**Commissioner for Patents**  
Fax Number: (571) 273-8300  
Phone Number: (571) 272-0709

**Examiner's Name:** Taofiq A. Solola  
**Group number:** 1625  
**Phone number:** (571) 272-0709

This message is from:

Name: Sylvia A. Ayler  
Fax number: (732) 594-2250  
Phone number: (732) 594-4909

**RE:** USSN: 10/570,913  
Filing Date: March 1, 2006  
Applicants' Ref.: Case 21437Y  
For: OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR  
HYPERTENSION

NUMBER OF PAGES BEING TRANSMITTED (INCLUDING COVER): 17

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL (732) 594-1251

**CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark  
Office on the date shown below

Type or print name of person signing certification

Christine M. Dona

Signature Christine M. Dona

Date July 22, 2008

RECEIVED  
CENTRAL FAX CENTER  
JUL 22 2008

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Dong-Ming Shen  
Serial No. : 10/570,913 Case No.: 21437YP Art Unit:  
Filed : March 3, 2006 1623  
For : Ophthalmic Compositions for Treating Ocular Hypertension Examiner:  
Taofiq A. Solola

Commissioner for Patents  
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

Serial No.: 10/570,913  
 Case No.: 21437YP  
 Page 2

RECEIVED  
 CENTRAL FAX CENTER  
 JUL 22 2008

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.


Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(d), this Information Disclosure Statement is being filed after the mailing of a Notice of Allowance under § 1.311. Each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

You are authorized to charge Merck Deposit account No. 13-2755 for the fee pursuant to § 1.176. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By

  
 Sylvia A. Ayler  
 Reg. No. 36,436  
 Attorney for Applicant

MERCK & CO., Inc.  
 P.O. Box 2000  
 Rahway, New Jersey 07065-0907  
 (732) 594-4909

Date: July 22, 2008